Literature DB >> 28039946

Why do patients die after a liver transplantation?

Kim E Daniel1, Jens Eickhoff1, Michael R Lucey1.   

Abstract

BACKGROUND: As more patients achieve long-term survival, it has become important to understand mortality in liver transplantation (LT) recipients.
METHODS: We conducted retrospective reviews of long-term outcome in two adult LT cohorts: 85 031 in the United Network for Organ Sharing (UNOS) database and 1458 transplanted at the University of Wisconsin (UW).
RESULTS: During median follow-up of 3.2 years (UNOS) and 6.6 years (UW), 35.1% of UNOS patients and 44.2% of UW patients died; 43.1% of all UNOS deaths occurred in year 1 compared to 25.1% in the UW cohort. Deaths due to infection (other than viral hepatitis) or cardiovascular (CV) causes were most frequent in year 1 in both cohorts and then persisted at lower rates. In contrast, death from malignancy increased after year 1 to peak in years 1-5. Deaths due to rejection, hepatitis, or graft failure were infrequent. In the UW cohort, de novo malignancy was more common than recurrent tumor and correlated with smoking history.
CONCLUSIONS: A coordinated holistic approach that focuses on limiting immunosuppression, infection, risky behaviors, and CV risks, while screening for cancer, is needed to extend the healthy lives of LT recipients.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cause of death; infection; liver transplantation; long-term survivors; malignancy; mortality

Mesh:

Year:  2017        PMID: 28039946     DOI: 10.1111/ctr.12906

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  9 in total

Review 1.  Substance use disorders before and after liver transplantation.

Authors:  Jason L Eccleston; Michael R Lucey
Journal:  Clin Liver Dis (Hoboken)       Date:  2017-10-31

2.  Transient Mixed Chimerism With Nonmyeloablative Conditioning Does Not Induce Liver Allograft Tolerance in Nonhuman Primates.

Authors:  Sulemon Chaudhry; Yojiro Kato; Joshua Weiner; Paula Alonso-Guallart; Sam Baker; David C Woodland; Jay H Lefkowitch; Raimon Duran-Struuck; Hugo P Sondermeijer; Jonah Zitsman; Mallory L Sears; Anette Wu; Brian Karolewski; Philipp J Houck; Mercedes Martinez; Tomoaki Kato; Megan Sykes; Adam D Griesemer
Journal:  Transplantation       Date:  2020-04-06       Impact factor: 4.939

3.  Sixteen-Year Cohort of Liver Transplantation in the National Health System in Brazil: Analysis of Immunosuppression Maintenance Therapies.

Authors:  Guilherme Fagundes Nascimento; Rosângela Maria Gomes; Juliana Alvares-Teodoro; Nélio Gomes Ribeiro; Mariângela Leal Cherchiglia; Charles Simão-Filho; Francisco Assis Acurcio; Tulio Tadeu Rocha Sarmento; Ludmila Peres Gargano; Augusto Afonso Guerra
Journal:  Front Pharmacol       Date:  2020-10-06       Impact factor: 5.810

4.  Reducing Immunosuppression in Patients with De Novo Lung Carcinoma after Liver Transplantation Could Significantly Prolong Survival.

Authors:  Sina Pesthy; Elisa Wegener; Ramin Raul Ossami Saidy; Lea Timmermann; Deniz Uluk; Mustafa Aydin; Tomasz Dziodzio; Wenzel Schoening; Georg Lurje; Robert Öllinger; Nikolaj Frost; Uli Fehrenbach; Jens-Carsten Rückert; Jens Neudecker; Johann Pratschke; Dennis Eurich
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

5.  De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature.

Authors:  Tommaso Maria Manzia; Roberta Angelico; Carlo Gazia; Ilaria Lenci; Martina Milana; Oludamilola T Ademoyero; Domiziana Pedini; Luca Toti; Marco Spada; Giuseppe Tisone; Leonardo Baiocchi
Journal:  World J Gastroenterol       Date:  2019-09-21       Impact factor: 5.742

6.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.

Authors:  Debashis Haldar; Barbara Kern; James Hodson; Matthew James Armstrong; Rene Adam; Gabriela Berlakovich; Josef Fritz; Benedikt Feurstein; Wolfgang Popp; Vincent Karam; Paolo Muiesan; John O'Grady; Neville Jamieson; Stephen J Wigmore; Jacques Pirenne; Seyed Ali Malek-Hosseini; Ernest Hidalgo; Yaman Tokat; Andreas Paul; Johann Pratschke; Michael Bartels; Pavel Trunecka; Utz Settmacher; Massimo Pinzani; Christophe Duvoux; Philip Noel Newsome; Stefan Schneeberger
Journal:  J Hepatol       Date:  2019-05-07       Impact factor: 25.083

7.  Intrahepatic De Novo Tumors in Liver Recipients are Highly Associated With Recurrent Viral Hepatitis.

Authors:  Michael J Pflüger; Max M Maurer; Karl H Hillebrandt; Andreas Andreou; Dominik Geisel; Moritz Schmelzle; Johann Pratschke; Dennis Eurich
Journal:  J Clin Exp Hepatol       Date:  2020-11-25

8.  Transient-mixed Chimerism With Nonmyeloablative Conditioning Does Not Induce Liver Allograft Tolerance in Nonhuman Primates.

Authors:  Sulemon Chaudhry; Yojiro Kato; Joshua Weiner; Paula Alonso-Guallart; Sam Baker; David C Woodland; Jay H Lefkowitch; Raimon Duran-Struuck; Hugo P Sondermeijer; Jonah Zitsman; Mallory L Sears; Anette Wu; Brian Karolewski; Philipp J Houck; Mercedes Martinez; Tomoaki Kato; Megan Sykes; Adam D Griesemer
Journal:  Transplantation       Date:  2020-08       Impact factor: 5.385

9.  Posttransplant muscle mass measured by urinary creatinine excretion rate predicts long-term outcomes after liver transplantation.

Authors:  Suzanne P Stam; Maryse C J Osté; Michele F Eisenga; Hans Blokzijl; Aad P van den Berg; Stephan J L Bakker; Vincent E de Meijer
Journal:  Am J Transplant       Date:  2018-06-03       Impact factor: 8.086

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.